ERBB2 and breast carcinoma: These results suggest that continued use of trastuzumab in HER2+ breast cancer with loss of PTEN function induces EMT, and consequent transforms molecular subtype from HER2+ to triple negative, which requires unique treatment options to improve patient survival.